GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stoke Therapeutics Inc (STU:0GT) » Definitions » Short Percentage of Float

Stoke Therapeutics (STU:0GT) Short Percentage of Float


View and export this data going back to 2019. Start your Free Trial

What is Stoke Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Stoke Therapeutics's Short Percentage of Float

For the Biotechnology subindustry, Stoke Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stoke Therapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stoke Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Stoke Therapeutics's Short Percentage of Float falls into.


Stoke Therapeutics (STU:0GT) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stoke Therapeutics Inc (STU:0GT) » Definitions » Short Percentage of Float
Comparable Companies
APLT ALLK VSTM AKBA ZVRA STRO GLUE IKNA LYRA OBIO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
STOK:USA
Address
45 Wiggins Avenue, Bedford, MA, USA, 01730
Website
https://www.stoketherapeutics.com
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The company primarily operates in the U.S.

Stoke Therapeutics (STU:0GT) Headlines

No Headlines